Beliefs in cardiac troponin testing [6]

Clinical Chemistry

Volumn 51, Issue 9, 2005, Pages 1755-1756

  Eriksson, Susann ^a   Pettersson, Kim ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOCHEMICAL MARKER; CREATINE KINASE MB; MYOGLOBIN; TROPONIN;

CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; IMMUNOASSAY; LETTER; PROTEIN ANALYSIS;

AUTOANTIBODIES; FALSE NEGATIVE REACTIONS; HUMANS; IMMUNOASSAY; MYOCARDIAL INFARCTION; TROPONIN I;

EID: 24144454805     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.056580     Document Type: Letter

References (14)

1. Panteghini M. Selection of antibodies and epitopes for cardiac troponin immunoassays: should we revise our evidence-based beliefs? Clin Chem 2005;51:803-4.
2. Eriksson S, Halenius H, Pulkki K, Hellman J, Pettersson K. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin Chem 2005;51:839-47.
3. Eriksson S, Junikka M, Laitinen P, Majamaa-Voltti K, Alfthan H, Pettersson K. Negative interference in cardiac troponin I immunoassays from a frequently occurring serum and plasma component. Clin Chem 2003;49: 1095-104.
4. Eriksson S, Ilva T, Becker C, Lund J, Porela P, Pulkki K, et al. Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. Clin Chem 2005;51:848-55.
5. Eriksson S, Junikka M, Pettersson K. An interfering component in cardiac troponin I immunoassays-its nature and inhibiting effect on the binding of antibodies against different epitopes. Clin Biochem 2004;37:472-80.
6. Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001;39:175-9.
7. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
8. Koukkunen H, Penttilä K, Kemppainen A, Penttilä I, Halinen MO, Rantanen T, et al. Differences in the diagnosis of myocardial infarction by troponin T compared with clinical and epidemiologic criteria. Am J Cardiol 2001;88:727-31.
9. Kontos MC, Fritz LM, Anderson FP, Tatum JL, Ornato JP, Jesse RL. Impact of the troponin standard on the prevalence of acute myocardial infarction. Am Heart J 2003;146:446-52.
10. Venge P, Johnston N, Lagerqvist B, Wallentin L, Lindahl B. Clinical and analytical performance of the Liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC-II substudy. Clin Chem 2003; 49:880-6.
11. Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). Am J Cardiol 2002;89:1035-41.
12. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810-24.
13. Ilva T, Eriksson S, Lund J, Porela P, Mustonen H, Pettersson K, et al. Improved early risk stratification and diagnosis of myocardial infarction, using a novel troponin I assay concept. Eur J Clin Invest 2005;35:112-6.
14. Eriksson S, Junikka M, Alfthan H, Pettersson K. Do troponin autoantibodies negatively influence measurement of troponin T? [Abstract]. Clin Chim Acta 2005;355(Suppl 1):S95.